Strikingly, and consistent with the NY-ESO model, urelumab* treatment alone significantly reduced the number of CD8+ cells in the tumor compared to MCLA-145 and this was associated with an increase in the frequency of CD4+ T cells and PD-L1+ monocytes (Fig. 4g). Here, CD274 is linked to neoplasm.